Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors
[Display omitted] A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two...
Gespeichert in:
Veröffentlicht in: | Bioorganic & medicinal chemistry 2019-01, Vol.27 (2), p.255-264 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 264 |
---|---|
container_issue | 2 |
container_start_page | 255 |
container_title | Bioorganic & medicinal chemistry |
container_volume | 27 |
creator | Barinka, Cyril Novakova, Zora Hin, Niyada Bím, Daniel Ferraris, Dana V. Duvall, Bridget Kabarriti, Gabriel Tsukamoto, Reiji Budesinsky, Milos Motlova, Lucia Rojas, Camilo Slusher, Barbara S. Rokob, Tibor András Rulíšek, Lubomír Tsukamoto, Takashi |
description | [Display omitted]
A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII’s preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency. |
doi_str_mv | 10.1016/j.bmc.2018.11.022 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6374116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089618316110</els_id><sourcerecordid>30552009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-3a736cdec0fbc3615a17791bd274d1707fc90bd288854baa07c5e4d41814abeb3</originalsourceid><addsrcrecordid>eNp9kUtLJDEUhcPgoO3jB8xG8geqvLcq9UIQRBxtEFzMzDrkVW2arkqRpNX-95O2bdGNq5B7z_nCySHkF0KOgPXFMpeDygvANkfMoSh-kBmymmVl2eEBmUFXtxm0XX1EjkNYAkDBOjwkRyVUVQHQzcjLn-jXKq69WFExaqrcMK2jiNaNaSJFsIH2ztPJRTNGascnK-12S11PF6skHUQ0VAkv3etmMlO0WgRD53MqN2_jN0GWSEbv7c6HU_KzF6tgzt7PE_Lv9-3fm_vs4fFufnP9kClWYcxK0ZS10kZBL1VZYyWwaTqUumiYxgaaXnWQbm3bVkwKAY2qDNMMW2RCGlmekKsdd1rLwWiVQqSofPJ2EH7DnbD862a0T3zhnnldNgyxTgDcAZR3IXjTf3gR-LYFvuSpBb5tgSPy1ELynH9-9MOx__YkuNwJTIr-bI3nQVkzKqOtNypy7ew3-P_MApyt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Barinka, Cyril ; Novakova, Zora ; Hin, Niyada ; Bím, Daniel ; Ferraris, Dana V. ; Duvall, Bridget ; Kabarriti, Gabriel ; Tsukamoto, Reiji ; Budesinsky, Milos ; Motlova, Lucia ; Rojas, Camilo ; Slusher, Barbara S. ; Rokob, Tibor András ; Rulíšek, Lubomír ; Tsukamoto, Takashi</creator><creatorcontrib>Barinka, Cyril ; Novakova, Zora ; Hin, Niyada ; Bím, Daniel ; Ferraris, Dana V. ; Duvall, Bridget ; Kabarriti, Gabriel ; Tsukamoto, Reiji ; Budesinsky, Milos ; Motlova, Lucia ; Rojas, Camilo ; Slusher, Barbara S. ; Rokob, Tibor András ; Rulíšek, Lubomír ; Tsukamoto, Takashi</creatorcontrib><description>[Display omitted]
A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII’s preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2018.11.022</identifier><identifier>PMID: 30552009</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Carbamates - chemical synthesis ; Carbamates - chemistry ; Carbamates - metabolism ; Catalytic Domain ; Cell Line ; Crystal structure ; Drosophila - genetics ; Enzyme Assays ; Glutamate carboxypeptidase II ; Glutamate Carboxypeptidase II - antagonists & inhibitors ; Glutamate Carboxypeptidase II - chemistry ; Glutamate Carboxypeptidase II - metabolism ; Humans ; Hydrogen Bonding ; Metallopeptidase ; Models, Molecular ; Prostate-specific membrane antigen ; Protease Inhibitors - chemical synthesis ; Protease Inhibitors - chemistry ; Protease Inhibitors - metabolism ; Protein Binding ; Quantum Theory ; Stereoisomerism ; Urea - analogs & derivatives ; Urea - chemical synthesis ; Urea - chemistry ; Urea - metabolism</subject><ispartof>Bioorganic & medicinal chemistry, 2019-01, Vol.27 (2), p.255-264</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-3a736cdec0fbc3615a17791bd274d1707fc90bd288854baa07c5e4d41814abeb3</citedby><cites>FETCH-LOGICAL-c451t-3a736cdec0fbc3615a17791bd274d1707fc90bd288854baa07c5e4d41814abeb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bmc.2018.11.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30552009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barinka, Cyril</creatorcontrib><creatorcontrib>Novakova, Zora</creatorcontrib><creatorcontrib>Hin, Niyada</creatorcontrib><creatorcontrib>Bím, Daniel</creatorcontrib><creatorcontrib>Ferraris, Dana V.</creatorcontrib><creatorcontrib>Duvall, Bridget</creatorcontrib><creatorcontrib>Kabarriti, Gabriel</creatorcontrib><creatorcontrib>Tsukamoto, Reiji</creatorcontrib><creatorcontrib>Budesinsky, Milos</creatorcontrib><creatorcontrib>Motlova, Lucia</creatorcontrib><creatorcontrib>Rojas, Camilo</creatorcontrib><creatorcontrib>Slusher, Barbara S.</creatorcontrib><creatorcontrib>Rokob, Tibor András</creatorcontrib><creatorcontrib>Rulíšek, Lubomír</creatorcontrib><creatorcontrib>Tsukamoto, Takashi</creatorcontrib><title>Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors</title><title>Bioorganic & medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>[Display omitted]
A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII’s preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency.</description><subject>Animals</subject><subject>Carbamates - chemical synthesis</subject><subject>Carbamates - chemistry</subject><subject>Carbamates - metabolism</subject><subject>Catalytic Domain</subject><subject>Cell Line</subject><subject>Crystal structure</subject><subject>Drosophila - genetics</subject><subject>Enzyme Assays</subject><subject>Glutamate carboxypeptidase II</subject><subject>Glutamate Carboxypeptidase II - antagonists & inhibitors</subject><subject>Glutamate Carboxypeptidase II - chemistry</subject><subject>Glutamate Carboxypeptidase II - metabolism</subject><subject>Humans</subject><subject>Hydrogen Bonding</subject><subject>Metallopeptidase</subject><subject>Models, Molecular</subject><subject>Prostate-specific membrane antigen</subject><subject>Protease Inhibitors - chemical synthesis</subject><subject>Protease Inhibitors - chemistry</subject><subject>Protease Inhibitors - metabolism</subject><subject>Protein Binding</subject><subject>Quantum Theory</subject><subject>Stereoisomerism</subject><subject>Urea - analogs & derivatives</subject><subject>Urea - chemical synthesis</subject><subject>Urea - chemistry</subject><subject>Urea - metabolism</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtLJDEUhcPgoO3jB8xG8geqvLcq9UIQRBxtEFzMzDrkVW2arkqRpNX-95O2bdGNq5B7z_nCySHkF0KOgPXFMpeDygvANkfMoSh-kBmymmVl2eEBmUFXtxm0XX1EjkNYAkDBOjwkRyVUVQHQzcjLn-jXKq69WFExaqrcMK2jiNaNaSJFsIH2ztPJRTNGascnK-12S11PF6skHUQ0VAkv3etmMlO0WgRD53MqN2_jN0GWSEbv7c6HU_KzF6tgzt7PE_Lv9-3fm_vs4fFufnP9kClWYcxK0ZS10kZBL1VZYyWwaTqUumiYxgaaXnWQbm3bVkwKAY2qDNMMW2RCGlmekKsdd1rLwWiVQqSofPJ2EH7DnbD862a0T3zhnnldNgyxTgDcAZR3IXjTf3gR-LYFvuSpBb5tgSPy1ELynH9-9MOx__YkuNwJTIr-bI3nQVkzKqOtNypy7ew3-P_MApyt</recordid><startdate>20190115</startdate><enddate>20190115</enddate><creator>Barinka, Cyril</creator><creator>Novakova, Zora</creator><creator>Hin, Niyada</creator><creator>Bím, Daniel</creator><creator>Ferraris, Dana V.</creator><creator>Duvall, Bridget</creator><creator>Kabarriti, Gabriel</creator><creator>Tsukamoto, Reiji</creator><creator>Budesinsky, Milos</creator><creator>Motlova, Lucia</creator><creator>Rojas, Camilo</creator><creator>Slusher, Barbara S.</creator><creator>Rokob, Tibor András</creator><creator>Rulíšek, Lubomír</creator><creator>Tsukamoto, Takashi</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190115</creationdate><title>Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors</title><author>Barinka, Cyril ; Novakova, Zora ; Hin, Niyada ; Bím, Daniel ; Ferraris, Dana V. ; Duvall, Bridget ; Kabarriti, Gabriel ; Tsukamoto, Reiji ; Budesinsky, Milos ; Motlova, Lucia ; Rojas, Camilo ; Slusher, Barbara S. ; Rokob, Tibor András ; Rulíšek, Lubomír ; Tsukamoto, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-3a736cdec0fbc3615a17791bd274d1707fc90bd288854baa07c5e4d41814abeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Carbamates - chemical synthesis</topic><topic>Carbamates - chemistry</topic><topic>Carbamates - metabolism</topic><topic>Catalytic Domain</topic><topic>Cell Line</topic><topic>Crystal structure</topic><topic>Drosophila - genetics</topic><topic>Enzyme Assays</topic><topic>Glutamate carboxypeptidase II</topic><topic>Glutamate Carboxypeptidase II - antagonists & inhibitors</topic><topic>Glutamate Carboxypeptidase II - chemistry</topic><topic>Glutamate Carboxypeptidase II - metabolism</topic><topic>Humans</topic><topic>Hydrogen Bonding</topic><topic>Metallopeptidase</topic><topic>Models, Molecular</topic><topic>Prostate-specific membrane antigen</topic><topic>Protease Inhibitors - chemical synthesis</topic><topic>Protease Inhibitors - chemistry</topic><topic>Protease Inhibitors - metabolism</topic><topic>Protein Binding</topic><topic>Quantum Theory</topic><topic>Stereoisomerism</topic><topic>Urea - analogs & derivatives</topic><topic>Urea - chemical synthesis</topic><topic>Urea - chemistry</topic><topic>Urea - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barinka, Cyril</creatorcontrib><creatorcontrib>Novakova, Zora</creatorcontrib><creatorcontrib>Hin, Niyada</creatorcontrib><creatorcontrib>Bím, Daniel</creatorcontrib><creatorcontrib>Ferraris, Dana V.</creatorcontrib><creatorcontrib>Duvall, Bridget</creatorcontrib><creatorcontrib>Kabarriti, Gabriel</creatorcontrib><creatorcontrib>Tsukamoto, Reiji</creatorcontrib><creatorcontrib>Budesinsky, Milos</creatorcontrib><creatorcontrib>Motlova, Lucia</creatorcontrib><creatorcontrib>Rojas, Camilo</creatorcontrib><creatorcontrib>Slusher, Barbara S.</creatorcontrib><creatorcontrib>Rokob, Tibor András</creatorcontrib><creatorcontrib>Rulíšek, Lubomír</creatorcontrib><creatorcontrib>Tsukamoto, Takashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bioorganic & medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barinka, Cyril</au><au>Novakova, Zora</au><au>Hin, Niyada</au><au>Bím, Daniel</au><au>Ferraris, Dana V.</au><au>Duvall, Bridget</au><au>Kabarriti, Gabriel</au><au>Tsukamoto, Reiji</au><au>Budesinsky, Milos</au><au>Motlova, Lucia</au><au>Rojas, Camilo</au><au>Slusher, Barbara S.</au><au>Rokob, Tibor András</au><au>Rulíšek, Lubomír</au><au>Tsukamoto, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors</atitle><jtitle>Bioorganic & medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2019-01-15</date><risdate>2019</risdate><volume>27</volume><issue>2</issue><spage>255</spage><epage>264</epage><pages>255-264</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>[Display omitted]
A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII’s preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30552009</pmid><doi>10.1016/j.bmc.2018.11.022</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0968-0896 |
ispartof | Bioorganic & medicinal chemistry, 2019-01, Vol.27 (2), p.255-264 |
issn | 0968-0896 1464-3391 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6374116 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Animals Carbamates - chemical synthesis Carbamates - chemistry Carbamates - metabolism Catalytic Domain Cell Line Crystal structure Drosophila - genetics Enzyme Assays Glutamate carboxypeptidase II Glutamate Carboxypeptidase II - antagonists & inhibitors Glutamate Carboxypeptidase II - chemistry Glutamate Carboxypeptidase II - metabolism Humans Hydrogen Bonding Metallopeptidase Models, Molecular Prostate-specific membrane antigen Protease Inhibitors - chemical synthesis Protease Inhibitors - chemistry Protease Inhibitors - metabolism Protein Binding Quantum Theory Stereoisomerism Urea - analogs & derivatives Urea - chemical synthesis Urea - chemistry Urea - metabolism |
title | Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A01%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structural%20and%20computational%20basis%20for%20potent%20inhibition%20of%20glutamate%20carboxypeptidase%20II%20by%20carbamate-based%20inhibitors&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Barinka,%20Cyril&rft.date=2019-01-15&rft.volume=27&rft.issue=2&rft.spage=255&rft.epage=264&rft.pages=255-264&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2018.11.022&rft_dat=%3Cpubmed_cross%3E30552009%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30552009&rft_els_id=S0968089618316110&rfr_iscdi=true |